Structure Therapeutics Inc. Sponsored ADR $GPCR Stake Lessened by Flax Pond Capital LLC

Flax Pond Capital LLC cut its stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 26.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,000 shares of the company’s stock after selling 12,721 shares during the period. Structure Therapeutics accounts for 1.4% of Flax Pond Capital LLC’s portfolio, making the stock its 26th largest position. Flax Pond Capital LLC owned approximately 0.05% of Structure Therapeutics worth $1,735,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in the stock. CWM LLC increased its position in shares of Structure Therapeutics by 35.2% in the 4th quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 125 shares during the last quarter. Sterling Capital Management LLC bought a new position in shares of Structure Therapeutics during the first quarter worth about $28,000. State of Wyoming acquired a new position in Structure Therapeutics in the second quarter worth about $28,000. Police & Firemen s Retirement System of New Jersey acquired a new position in Structure Therapeutics in the fourth quarter worth about $127,000. Finally, Assetmark Inc. increased its holdings in Structure Therapeutics by 21.4% in the first quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock valued at $123,000 after buying an additional 449 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Stock Up 4.5%

Shares of NASDAQ:GPCR opened at $49.47 on Friday. The company has a market cap of $3.52 billion, a PE ratio of -56.86 and a beta of -1.50. Structure Therapeutics Inc. Sponsored ADR has a fifty-two week low of $15.80 and a fifty-two week high of $94.90. The firm has a 50-day simple moving average of $46.33 and a 200 day simple moving average of $55.30.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. As a group, research analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Friday, July 17th. HC Wainwright decreased their target price on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Thursday, June 11th. Canaccord Genuity Group assumed coverage on Structure Therapeutics in a report on Monday, April 27th. They issued a “buy” rating and a $101.00 price target for the company. Finally, Wall Street Zen lowered Structure Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $110.55.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.